Quince Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

IRulya Therapeutics

14/11/2024 03:59

* Quince Therapeutics Inc  QNCX.OQ  reported a quarterly
adjusted
loss of 13 cents​​ per share for the quarter ended September
30.  The mean expectation of two analysts for the quarter was
for a loss of 15 cents per share. Wall Street expected
results to range from -21 cents to -10 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Quince Therapeutics Inc's reported EPS for the quarter was
a
loss of 13 cents​.
    * The company reported a quarterly loss of $5.49 million.
    * Quince Therapeutics Inc shares had risen by 116.4% this
quarter and gained 60.0% so far this year.

FORECAST CHANGES
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Quince
Therapeutics Inc is 9.00 
This summary was machine generated from LSEG data November 14 at
03:59 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.15          -0.13          Beat